Tag: Novo Nordisk

Analysis: Drug industry bets on new blockbusters in 2013

Your Health Matters

Logo of Swiss pharmaceutical company Roche is pictured in RotkreuzLONDON/NEW YORK (Reuters) – Drugmakers are betting that a new wave of medicines for cancer, diabetes, heart disease, multiple sclerosis and hepatitis will shape up as tomorrow's blockbusters in the coming 12 months. With the industry regaining some of its swagger after winning 39 new drug approvals last year – a record only beaten in 1996 – there are signs the improving trend could continue through 2013. Roche, GlaxoSmithKline, Eli Lilly, Biogen Idec, Gilead Sciences and Novo Nordisk are among those with important new products reaching a critical point in development this year. …

, , ,

Novo Nordisk wins EU agency backing for new insulin

Your Health Matters

LONDON/COPENHAGEN (Reuters) – Novo Nordisk’s ultra long-acting insulin Tresiba has been recommended for approval by the European Medicines Agency in an important boost for the Danish drugmaker’s key new product. The European endorsement, announced by the London-based agency and the company on Friday, follows regulatory delays for the diabetes treatment in the United States, where the bulk of future sales are expected to be generated. …

, , ,

Novo Nordisk says Victoza superior to Amylin rival

Your Health Matters

COPENHAGEN (Reuters) – Denmark’s Novo Nordisk, the world’s biggest insulin producer, said on Monday a study had confirmed its diabetes drug Victoza provided greater reductions in blood sugar levels than rival drug Byetta from Amylin. Novo Nordisk said in a statement the study, presented at the 72nd Annual Scientific Sessions of the ADA in Philadelphia, showed more patients appeared to favor a drug given by injection over a drug which is given orally. The study also confirmed weight loss and cost-effectiveness in the use of Victoza, Novo Nordisk said. …

, ,